Lowering mutant Huntingtin is a consensus therapeutic strategy for Huntington's 
disease. In this issue of Neuron, Kordasiewicz et al. (2012) show the benefit of 
transient antisense oligonucleotide (ASO) therapy to degrade Huntingtin mRNA and 
elicit sustained therapeutic benefit in HD mice.